DWC 202002
Alternative Names: DWC202002Latest Information Update: 28 May 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Unspecified in South Korea (PO, Tablet)
- 13 Apr 2020 Preclinical trials in Unspecified in South Korea (PO) before April 2020 (NCT04343547)
- 13 Apr 2020 Daewoong Pharmaceutical plans a phase I trial (In volunteers) in April 2020 in South Korea (PO, Tablet) (NCT04343547)